Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant HAIP chemotherapy after resection of colorectal liver metastases
2018-001696-21Phase 3Active
- Sponsor
- Erasmus MC Cancer Institute
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of floxuridine in colorectal cancer (CRC) and colorectal cancer liver metastasis (CRLM) (2 arms), sponsored by Erasmus MC Cancer Institute. Primary endpoint: Progression-free survival. Started Jun 2018; status: active.
02
Drugs
floxuridine
03
Conditions
colorectal cancer (CRC)colorectal cancer liver metastasis (CRLM)
Beyond the preview
Go deeper on 2018-001696-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001696-21.